Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation  by Rosenblatt, Jacalyn et al.
Biol Blood Marrow Transplant 19 (2013) S109eS128ASBMT BEST ABSTRACT AWARDS FOR BASIC SCIENCE1
Blockade of PD-1 in Combination with Dendritic Cell/
Myeloma Fusion Cell Vaccination Following Autologous
Stem Cell Transplantation
Jacalyn Rosenblatt 1, Irit Avivi 2, David Vasir 3, Lynne Uhl 1,
Tami Katz 2, Poorvi Somaiya 1, Heidi Mills 1, Robin Joyce 1,
James D. Levine 1, Vassiliki A. Boussiotis 1, Katarina Luptakova 1,
Jon Arnason 1, Natalie Drummy1, Carol Delaney 1,
Emma Breault 1, Viki Held 2, Lina Bisharat 2,
Nancy Giallombardo 1, Jamie Mortellite 1, Judith Wagoner 1,
Michael Schickler 4, Rinat Rotem-Yehudar 4,
Paul G. Richardson 3, Jacob Laubach 3, Kenneth Anderson 3,
Nikhil Munshi 3, Jacob Rowe 2, Donald Kufe 3, David Avigan 1.
1 Beth Israel Deaconess Medical Center, Boston, MA; 2 Rambam
Medical Center, Haifa, Israel; 3 Dana Farber Cancer Institute,
Boston, MA; 4 CureTech, Ltd
Autologous stem cell transplantation (ASCT) for multiple
myeloma (MM) offers a unique setting to explore the role
of immunotherapy in eradicating residual disease. A chal-
lenge to developing an effective anti-tumor immune
response is overcoming the suppressive effect of inhibitory
pathways, including the PD-1/PDL1 pathway. We are con-
ducting a clinical trial in which MM patients are treated
with an anti-PD1 antibody (CT-011) alone (Cohort 1) and in
combination with a dendritic cell/myeloma fusion cell
vaccine (Cohort 2) following ASCT. To date, 27 patients have
been enrolled into Cohort 1, in which patients receive three
infusions of CT-011 at doses of 3 mg/kg given at 6 week
intervals beginning 1-3 months following ASCT. Mean age
of the patients is 57 years; 61% are male. Twelve patients
have received at least two infusions of CT-011. CT-011 has
been well tolerated, with possibly related adverse events
consisting of transient grade 1-2 leukopenia, diarrhea,
fatigue, arthralgia, rash, and peri-orbital edema. One
patient developed grade 3 neutropenia, which resolved
after two days without growth factor. Immunologic
response was determined by quantifying circulating tumor
reactive T cells prior to each dose of CT-011 and at 1, 3, 6
months following the last infusion, as deﬁned by the
percentage of T cells expressing IFNg in response to ex vivo
exposure to autologous tumor lysate. Four patients have
completed 6 months of follow up, and are evaluable for
immune response. CT-011 was associated with the dramatic
expansion of myeloma speciﬁc T cells. Mean percentage of
circulating tumor reactive CD4þ and CD8þ T cells increased
from 1.5 and 1.96 respectively prior to the ﬁrst infusion of
CT-011, to 4.26 and 8.28 respectively 1 month following the
third infusion. As determined by tetramer staining in the
subset of patients who are HLA A2.1, CT-011 resulted in
a mean 9 fold expansion of T cells speciﬁc to the MUC1
antigen. Notably, immunologic response to CT-011 persists
at 6 months following completion of therapy. Clinical
response, as determined by time to disease progression,
will be determined with longer follow up. We have initi-
ated enrollment to Cohort 2, in which patients will be
vaccinated with an autologous DC/myeloma fusion vaccine
1 week prior to each dose of CT-011. These data demon-
strate that CT-011 results in the expansion of tumor reac-
tive lymphocytes in the early post-transplant period,
providing an ideal platform for combination with a tumor
vaccine.2
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Introduction: Histone deacetylase inhibitors (HDACi) are an
important class of anti-cancer agent and have been shown by
us and others to attenuate experimental GVHD in multiple
murine models. We and others have shown that HDACi
reduce proinﬂammatory cytokines, modulate APC functions
through induction of IDO in a STAT-3-dependent manner,
and increase Treg numbers (PNAS 2004; JCI 2008; Nat Med
2007). We have now translated our experimental observa-
tions from murine models into a ﬁrst-in-human clinical trial
to test the hypothesis that HDAC inhibition is safe and
reduces GVHD severity in patients undergoing matched
related donor (MRD) reduced intensity conditioning (RIC)
HSCT.
Methods: 45 subjects were enrolled from two centers in
a phase I/II trial that added the HDACi, vorinostat 100mg BID,
to a standard GVHD prophylaxis regimen (tacrolimus and
MMF). The primary endpoint was the incidence of day 100
grade 2-4 acute GVHD with a risk of 25% compared with 42%
in historical controls. The RIC regimen consisted of ﬂudar-
abine 40 mg/m2 (4 days) and busulfan 3.2 mg/kg (2 days).
Based on our experimental observations, we obtained 4
blood samples from study subjects: (1) prior to study drug
administration (pre-therapy), (2) day 1, (3) day 30, and (4)
day 100 to perform correlative studies.
Results: Vorinostat was safe, tolerable, and feasible to
administer after MRD RIC HSCT. All study subjects have
engrafted and there have been no DLTs. Donor chimerism
was 95%, 97.5%, and 100% by day 30, 100 and 365, respec-
tively. We performed pharmacokinetic studies of vorinostat
in blood samples on day 1 at: pre-dose (immediately before
the ﬁrst dose of the day), 0.5, 1, 2, 3, 4, 6, and 12h (immedi-
ately before the second dose of the day). Themean half-life of
study subjects was 1.8h (1.3-2.3h) resulting in a mean AUC,
Cmax and Tmax 2.51.4mM*h, 0.491.0mM, and 2.6h (1-4h),
respectively. We then investigated the pharmaco-dynamic
effects of HDAC inhibition on day 30 after BMT. Study
patients demonstrated enhanced H4 acetylation in PBMCs
compared with historical controls (P¼0.009), suggesting that
HDAC enzymes were inhibited. We also determined the
functional impact of HDACi on PBMCs from study patients
and found that HDACi acetylated STAT-3 (P¼0.005),
enhanced IDO expression (P<0.0001), and reduced in vivo
TNF-a (P¼0.039) and IL-6 (P¼0.048) secretion and also ex
vivo following LPS stimulation (P<0.05). Study patients
showed increased numbers of CD4þCD25þCD127- T cell
population (Treg) (P¼0.04) and Foxp3þ expression by qPCR
(P¼0.006). Consistent with experimental and laboratory
data, the incidence of GVHD at day 100 (primary endpoint)
